

New EBV Vaccine in Development Uses Nano-Particles; The CBCD Reviews a Report

Research using nano-particles in vaccine development may enable an effective EBV vaccine to gain FDA approval in the near future. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, August 19, 2015 /EINPresswire.com/ --

“Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disease (CBCD) recommends taking [Gene-Eden-VIR](#) or [Novirin](#).” – Greg Bennett, CBCD

A new vaccine in development against the Epstein-Barr Virus (EBV) uses nano-technology to defeat the virus.

Nanoparticles are microscopic particles being investigated as potential delivery vehicles for vaccines. A study published in the journal Cell found that “In mice and monkeys, the nanoparticle-based vaccine triggered the animals' immune system to release powerful antibodies against Epstein-Barr.” (1) Dr. Jeffrey Cohen said that “The new findings suggest that this could be a promising approach for developing an Epstein-Barr virus vaccine for people.” Dr. Cohen is a virologist from the U.S. National Institute of Allergy and Infectious Diseases (NIAID). In contrast to Dr. Cohen's opinion, Dr. Paul Lee, an infectious disease expert, provided an alternative view, saying that while the work is promising, “there is still a long way to go before a vaccine that shows promise in mice and non-human primates will be

ready for safe and effective protection of people.” (1)

An FDA approved, effective vaccine against the Epstein-Barr Virus would be an important step forward for science, since “most people infected with the virus do not get ill or have only mild symptoms, and Epstein-Barr is a major cause of infectious



non-Hodgkin lymphoma.” (1)

The Center for the Biology of Chronic Disease (CBCD) is encouraged by the promising results of EBV vaccine studies in animals. However, the public should be aware that it is common for many vaccine candidates to fail during clinical trials. Also, developing an effective, therapeutic vaccine against the Epstein-Barr Virus (EBV) and gaining FDA approval takes time. Until any new anti-EBV vaccine is FDA approved, the CBCD recommends that infected individuals take Gene-Eden-VIR or Novirin, which are natural EBV remedies with a formula backed by clinical studies that followed FDA guidelines.

Click to learn more about [EBV symptoms](#).

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin formula is effective against the herpes family of viruses. The Epstein Barr Virus (EBV) is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the EBV ... reported a safe decrease in their symptoms following treatment with (the formula of Novirin).” (2) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Gene-Eden-VIR and Novirin can be ordered online on their respective websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their shared formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

What treatments are available for EBV infections?

“A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans.” (2) There are also natural antiviral products that studies show to be safe and effective in reducing EBV symptoms. Two of these products are Gene-Eden-VIR and Novirin.

“Based on the results of these studies, and the CBCD’s own research, we recommend that EBV

infected individuals take Gene-Eden-VIR or Novirin.” - Greg Bennett, CBCD

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure. However, two clinical studies showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was shown to safely and effectively reduce EBV symptoms. Additionally, it was designed to help the immune system target the latent virus.

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) "Epstein-Barr Vaccine Shows Promise" -newsmax.com - Published August 15, 2015

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.

